Scott Giacobello was appointed to the Lykos board of directors in May of 2024. Mr. Giacobello is an accomplished executive with more than 25 years of experience leading finance organizations. He is the chief financial officer (CFO) of Aadi Bioscience, Inc., a commercial-stage biopharmaceutical company developing precision therapies for genetically defined cancers. Prior to joining Aadi in 2021, Mr. Giacobello played a key role in the buildout of U.S. operations and commercial readiness in his role as CFO of GW Pharmaceuticals plc, leading the company’s financial strategy and raising more than $620 million ahead of its acquisition by Jazz Pharmaceuticals in 2021. Prior to GW, he served as CFO for Chase Pharmaceuticals Corporation, a clinical stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders, until it was acquired by Allergan in 2016. From 2008 through 2015, Mr. Giacobello held senior level finance positions at Allergan, Inc., most recently serving as vice president (VP) of finance for global research and development. While at Allergan, he also served as VP of corporate finance and VP of internal audit and compliance. Mr. Giacobello’s previous experience includes financial positions at the Black & Decker Corporation and Ernst & Young, LLP. He holds a bachelor’s degree in business administration from the University of Notre Dame and is a certified public accountant.
Board of Directors